Drugs / Leucostim
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02762799 | Jul → Nov 2016 | leukocyte disorder | Biocad | Completed | No outcome recorded |
| Phase 1 | NCT01820715 | Jun 2010 → Apr 2013 | diabetic neuropathy | Dong-A Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03343145 | Jan 2017 → Jan 2019 | breast cancer | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Leucostim | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02762799 ↗ |
| Known as | DA-3030 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01820715 ↗ |
| Route | Subcutaneous | “single subcutaneous injection Leucostim®” NCT02762799 ↗ |